Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
| Previous close | 299.00 |
| Open | 299.00 |
| Bid | 294.80 x 0 |
| Ask | 295.20 x 0 |
| Day's range | 292.00 - 299.20 |
| 52-week range | 189.03 - 302.00 |
| Volume | |
| Avg. volume | 335,378 |
| Market cap | 100.635B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 46.93 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A
Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of high-sustained factor VIII therapy, provided highly effective bleed protection in children.
- PR Newswire
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Second Quarter 2024
- PR Newswire
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting - on directed share issues of no more than 1,641,103 redeemable and convertible class C shares.
